Drug recall · August 20, 2025
Duloxetine Delayed-Release Capsules recall
Why: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. NDC 82009-032-10
- Lots / codes
Lot 240539C, Exp 1/31/2027
- Quantity
- 1,856 bottles
- Company
- Breckenridge Pharmaceutical, Inc., Berkeley Heights, NJ
- Distribution
- NJ, AZ, IN
- Initiated
- July 25, 2025 · Voluntary: Firm initiated
- Classified
- August 12, 2025
- Reported
- August 20, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Duloxetine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.